Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Comprehensive Loss

v3.24.1
Consolidated Statements of Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Product Revenue
Product Cost of Sales
Gross Income
Administrative Expenses 5,442,886 5,520,150
Research and Development Expenses 7,867,795 9,067,422
Stock Based Compensation 3,049,537 695,191
Warrant Issuance Expenses 762,834
Loss from Operations (17,123,052) (15,282,763)
Other (Income) Expenses    
Interest and Dividend Income (455,570) (83,991)
(Gain)/Loss on Sales of Marketable Securities (416) 5,964
Unrealized (Gain)/Loss on Marketable Securities (514) (2,958)
Change in fair value of Derivatives Liabilities (3,088,800)
Change in fair value of Warrant Liabilities (9,756,000)
Uninsured Casualty Losses 178,198 (4,442)
Total Other (Income) Expenses (13,123,102) (85,427)
Loss Before Income Tax (3,999,950) (15,197,336)
Income Tax Benefit
Net Loss (3,999,950) (15,197,336)
Preferred Stock Dividends 4,218,213
Net Income/(Loss) Attributable to Common Stockholders $ (8,218,163) $ (15,197,336)
Net loss per common share - basic $ (5.33) $ (11.74)
Net loss per common share - diluted $ (5.33) $ (11.74)
Weighted average common shares outstanding - basic 1,542,453 1,294,200
Weighted average common shares outstanding - diluted 1,542,453 1,294,200